Yes, in general in genomics there's always been a history of putting your data out almost as you generate it and making it available in the evolution of the science.
There was an earlier question in this area, but the challenge for us—and maybe our contribution to the drug pricing pressure—is to establish an independent diagnostic facility so that you can assess your patients and determine which patients should get which drug on objective criteria, as opposed to maybe a marketing push or manipulation. Our sense of where we can intervene might be on the characterization of the patients really objectively, so that health care systems can more easily deal with those cost pressures.